Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,481 shares of the biopharmaceutical company’s stock after buying an additional 3,487 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Alnylam Pharmaceuticals worth $27,942,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ALNY. Regeneron Pharmaceuticals Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $1,045,822,000. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $577,941,000. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock valued at $89,100,000 after acquiring an additional 315,182 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.4%

Alnylam Pharmaceuticals stock opened at $322.83 on Friday. The company has a market capitalization of $42.09 billion, a P/E ratio of -154.46 and a beta of 0.22. The firm’s fifty day simple moving average is $286.24 and its 200-day simple moving average is $263.26. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $326.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.16) EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ALNY shares. UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an “outperform” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $337.91.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.